...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Cancer Research and Therapy >Advances in targeted therapy and immunotherapy for treatment of lung cancer
【24h】

Advances in targeted therapy and immunotherapy for treatment of lung cancer

机译：靶向治疗和免疫疗法治疗肺癌的研究进展

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Personalized therapy based on targetable genetic aberrations has become a standard therapy for cases of lung adenocarcinoma (LADC) harboring EGFR mutations and ALK fusions. The effects of such personalized therapy are significantly positive with a higher response rate and longer survival compared to conventional chemotherapy. Therefore, further identification of druggable genetic aberrations and the development of molecular targeting drugs for them are required. For LADC, several new targeted drugs against driver mutations in EGFR , KRAS , HER2 , and BRAF ; and driver fusions involving ALK , RET , and ROS1 have been developed, and clinical trials of these new targeted drugs are currently being conducted. On the other hand, personalized therapy against driver mutations has not well progressed in squamous cell lung cancer and small cell lung cancer. For those subtypes, immunotherapy might be an effective treatment strategy.
机译：基于可靶向遗传畸变的个性化治疗已成为具有 EGFR突变和 ALK融合蛋白的肺腺癌（LADC）病例的标准治疗方法。与常规化学疗法相比，这种个性化疗法的效果显着阳性，具有更高的应答率和更长的生存期。因此，需要进一步鉴定可药物化遗传畸变并为它们开发分子靶向药物。对于LADC，有几种新的靶向药物可抵抗 EGFR， KRAS， HER2和 BRAF中的驱动子突变;已经开发出了涉及iALK，iRET和ROS1的驱动融合蛋白，目前正在对这些新的靶向药物进行临床试验。另一方面，在鳞状细胞肺癌和小细胞肺癌中，针对驾驶员突变的个性化治疗进展不佳。对于那些亚型，免疫疗法可能是一种有效的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号